icon
Getting Started
Scientific American
2022-02-01

A Psychedelic May Soon Go to the FDA for Approval to Treat Trauma

MDMA, known as Ecstasy in the clubs, gained high marks in a clinical trial for PTSD

Related News

Psychedelic Science 2025: Set and (Re)Setting

For its fifth installment, Psychedelic Science 2025 returned to Denver, offering three days of big ideas, heartfelt community, and some noticeable shifts in the psychedelic space. After the usual chaos of delayed flights and travel drama on Tuesday, we shared a collective sigh of relief as we finally arrived at the Colorado Convention Center, a mile high and ready to dive in.

Read More icon
New Paul Stamets Psychedelic Microdosing Study with MindMed and Numi Connections | New DMT Study

In this episode of the $Psyc Business Roundup, we’ll cover Algernon Pharmaceuticals (OTC: AGNPF, CSE: AGN) is planning to begin a clinical trial using DMT to treat acute strokes.

Read More icon
5 Athletes Who Healed With Psychedelic Therapy

Conventional mental health therapies have offered little help. But a growing number of professional athletes are finding the path back to a better life with a more unconventional therapy—psychedelics. These five athletes are leading the way in psychedelic therapy.

Read More icon
Could Psilocybin End Our Addiction Crisis?

Two doses of psilocybin over a period of eight weeks significantly reduced alcohol use and cravings for alcoholics. That’s according to early results of a New York University phase 2 study.

Read More icon
So, You’re Thinking of Doing Psychedelics?

So, you’re thinking of doing psychedelics and have no idea where to start. Join Mareesa Stertz from Lucid News and The Healing Powers as she gives an orientation to help newcomers understand what to expect when embarking on their first psychedelic journey and how to navigate these spaces safely and with grace.

Read More icon